Mittwoch, 05.08.2026, Calendar Week 32, 217. day of the year, 148 days remaining until EoY.

Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.

Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US62855J1043

Filter zurücksetzen

Do you already know our new terminal view? Click here.

FIGI: BBG000D9H9F1

MYGN

Myriad Genetics Inc

GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Diagnostics & Research · THEMEFOLIO: $HLTH

NAME

Myriad Genetics Inc

ISIN

US62855J1043

TICKER

MYGN

MIC

XNAS

REUTERS

MYGN.OQ

BLOOMBERG

MYGN US

Mi., 05.08.2026 Myriad Genetics

Newsfeed

MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN) | Myriad Genetics Inc

MYGN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Myriad Genetics | Myriad Genetics Inc

Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN) | Myriad Genetics Inc

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Myriad Genetics Inc

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 | Myriad Genetics Inc

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen | Myriad Genetics Inc

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer | Myriad Genetics Inc

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication | Myriad Genetics Inc

Myriad Genetics Names Raj Jampa as New Chief Technology Officer | Myriad Genetics Inc

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting | Myriad Genetics Inc

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) | Myriad Genetics Inc

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life | Myriad Genetics Inc

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan | Myriad Genetics Inc

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026 | Myriad Genetics Inc

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 | Myriad Genetics Inc

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan | Myriad Genetics Inc

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting | Myriad Genetics Inc

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer | Myriad Genetics Inc

Myriad Commercially Launches Precise MRD with Select Community Oncologists | Myriad Genetics Inc

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests | Myriad Genetics Inc

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution | Myriad Genetics Inc

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test | Myriad Genetics Inc

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 | Myriad Genetics Inc

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance | Myriad Genetics Inc

Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium | Myriad Genetics Inc

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health | Myriad Genetics Inc

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences | Myriad Genetics Inc

Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs | Myriad Genetics Inc

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution | Myriad Genetics Inc

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner | Myriad Genetics Inc

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025 | Myriad Genetics Inc

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel | Myriad Genetics Inc

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology | Myriad Genetics Inc

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression | Myriad Genetics Inc

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences | Myriad Genetics Inc

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer | Myriad Genetics Inc

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results | Myriad Genetics Inc

Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm | Myriad Genetics Inc

Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation | Myriad Genetics Inc

Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz | Myriad Genetics Inc

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting | Myriad Genetics Inc

Myriad Genetics Announces Inducement Awards | Myriad Genetics Inc

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer | Myriad Genetics Inc

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools | Myriad Genetics Inc

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth | Myriad Genetics Inc

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025 | Myriad Genetics Inc

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay | Myriad Genetics Inc

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History | Myriad Genetics Inc

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference | Myriad Genetics Inc

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference | Myriad Genetics Inc